Delving into the Latest Updates on COVID 2019 vaccine (Shenzhen Kangtai Biological Products) with Synapse

The study will be a multi-national, endpoint-driven, randomized, double-blind, placebo-controlled, adaptive study in which participating adults will be randomized 1:1 to receive 2 doses of either candidate vaccine or placebo on Day 0 and 28. A total of 28,000 healthy adults aged 18 years and older will be enrolled and followed for efficacy, safety, and immunogenicity evaluations.

Start Date01 May 2021

Sponsor / Collaborator

Shenzhen Kangtai Biological Products Co., Ltd.

[+1]

100 Clinical Results associated with COVID 2019 vaccine (Shenzhen Kangtai Biological Products)

Login to view more data

100 Translational Medicine associated with COVID 2019 vaccine (Shenzhen Kangtai Biological Products)

Login to view more data

100 Patents (Medical) associated with COVID 2019 vaccine (Shenzhen Kangtai Biological Products)

Login to view more data

8

Literatures (Medical) associated with COVID 2019 vaccine (Shenzhen Kangtai Biological Products)

01 May 2023·Ophthalmology

Navigating Coronavirus Disease 2019 Vaccination and Uveitis

Article

Author: Allen, Natalie ; Townend, Stephanie ; Sims, Joanne ; Jordan, Charlotte A ; McGhee, Charles N J ; Niederer, Rachael L

PURPOSETo identify rates of uveitis reactivation both before and after the coronavirus disease (COVID) 2019 vaccine in subjects with a previous diagnosis of uveitis.DESIGNRetrospective study.PARTICIPANTSSubjects were identified from the Inflammatory Eye Disease Registry at Auckland District Health Board diagnosed with uveitis between January 1, 2010, and December 31, 2020.METHODSDate of COVID vaccination was determined from the patient clinical record. Rate of flare was calculated for 3 months before vaccination and 3 months after each vaccination.MAIN OUTCOME MEASUREUveitis flare was defined as the presence of new uveitis activity or increased activity that required a change in uveitis treatment.RESULTSA total of 4184 eyes of 3008 patients were included in the study with a total of 8474 vaccinations given during the study period. Median age was 54.8 years, and 1474 (49.0%) were female. Noninfectious etiology was most common, occurring in 2296 patients (76.3%) and infectious etiology occurring in 712 patients (23.7%). Rate of uveitis flare was 12.3 per 1000 patient-months at baseline, 20.7 after the first dose, 15.0 after the second dose, 12.8 after the third dose, and 23.9 after the fourth dose. The median period of quiescence before flare was 3.9 years. An increase in uveitis flare was seen in both infectious uveitis (baseline 13.1 compared with 20.2 after first dose, 154% increase) and noninfectious uveitis (baseline 12.4 compared with 20.9 after first dose, 169% increase). Risk factors for uveitis flare were identified to be recurrent uveitis, chronic uveitis, shorter period of quiescence, and first dose of vaccine. Median time to uveitis flare was 0.53 months after the first vaccination, 1.74 months after the second vaccination, and 1.35 months after the third vaccination.CONCLUSIONSThe current study demonstrates an increased risk of uveitis flare after the first dose of COVID vaccination. This risk was highest in those with previous recurrences, chronic uveitis, and shorter period of quiescence.FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found after the references.

01 Jan 2023·Neurology India

A Novel Neuroimaging Finding

Article

Author: Mahajan, Ashima ; Sharma, Kalyan ; Oinam, Rahul ; Padma Srivastava, M Vasantha ; Nayak, Manoj K ; Anand, Pooja ; Gaikwad, Shailesh B ; Mishra, Biswa Mohan

Introduction:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which not only produces respiratory symptoms but is known to involve almost every system, and its neuroinvasive properties have been well demonstrated throughout the pandemic. Also, to combat the pandemic, there was rapid development and induction of various vaccination drives, following which many adverse events following immunization (AEFIs) have been reported, which include neurological complications as well.Method:We present a series of three cases, post vaccination, with and without a history of COVID illness that showed remarkably similar findings on magnetic resonance imaging (MRI).Result:A 38-year-old male presented with complaints of weakness of the bilateral lower limbs with sensory loss and bladder disturbance a day after receiving his first dose of ChadOx1 nCoV-19 (COVISHIELD) vaccine. A 50-year-old male with hypothyroidism characterized by autoimmune thyroiditis and impaired glucose tolerance experienced difficulty in walking 11.5 weeks after being administered with COVID vaccine (COVAXIN). A 38-year-old male presented with subacute onset progressive symmetric quadriparesis 2 months after their first dose of a COVID vaccine. The patient also had sensory ataxia, and his vibration sensation was impaired below C7. All three patients had typical pattern of involvement of the brain and spine on MRI with signal changes in bilateral corticospinal tracts, trigeminal tracts in the brain, and both lateral and posterior columns in the spine.Conclusion:This pattern of brain and spine involvement on MRI is a novel finding and is likely a result of post-vaccination/post-COVID immune-mediated demyelination.

01 Jan 2022·International journal of physiology, pathophysiology and pharmacology

Expected cost effectiveness of the fourth dose of COVID-19 vaccine against the omicron variant of COVID-19: a preliminary report.

Article

Author: Wiwanitkit, Viroj ; Mungmunpuntipantip, Rujittika

OBJECTIVESCOVID-19 immunization has been shown to be effective in the prevention of COVID-19. Traditionally, two doses of COVID-19 vaccines are required. Booster immunization is generally required when immunity has deteriorated.METHODSThe effectiveness of the alternate boost immunization protocol is still unknown. The authors of this study used a cost-effectiveness analysis, which is a retrospective analysis on datasets on cost and effectiveness, to examine the projected cost-effectiveness of boosting COVID-19 vaccination by a fourth dose.RESULTSThe cost-effectiveness of the fourth-dose COVID booster vaccine was found to be higher in this study.CONCLUSIONIt could imply that vaccinating against the current pandemic of the novel form, omicron, with the additional COVID-19 vaccine is a smarter idea.

100 Deals associated with COVID 2019 vaccine (Shenzhen Kangtai Biological Products)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
COVID-19	CN	Shenzhen Kangtai Biological Products Co., Ltd.	14 May 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	MY	Shenzhen Kangtai Biological Products Co., Ltd.	20 Jun 2021
Severe Acute Respiratory Syndrome	Preclinical	CN	Beijing Minhai Biological Technology Co., Ltd.	27 Oct 2020